Isis & Oncogenex announce positive phase II results for prostate cancer drug <a href="http://biz.yahoo.com/prnews/081203/law039.html?.v=101" target="_blank">http://biz.yahoo.com/prnews/081203/law039.html?.v=101</a> Isis isn't necessarily cheap at a $1 billion market cap but then again, given their number of products under development, partnerships, and patent estate, perhaps it is.